Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/3/26 20:30 | 6/1/26 | REPL | Health | BioPrd | Biological Products, (No Diag | Sarchi Christopher | MA | O | Chief Co | 5 | S | -284 | 7.88 | 0 | -36 | 193 | D | |||||||||||||||
5/20/26 16:18 | 5/18/26 | REPL | Health | BioPrd | Biological Products, (No Diag | Xynos Konstantinos | MA | O | Chief Me | 3 | S | -201 | 6.89 | 0 | -29 | 236 | D | |||||||||||||||
5/20/26 16:17 | 5/18/26 | REPL | Health | BioPrd | Biological Products, (No Diag | Schwendenman Andrew | MA | O | Chief Ac | 2 | S | -67 | 5.95 | 0 | -11 | 107 | D | |||||||||||||||
5/20/26 16:16 | 5/18/26 | REPL | Health | BioPrd | Biological Products, (No Diag | Astley-Sparke Philip | MA | D | 2 | S | -350 | 7.01 | 0 | -50 | 1,412 | D | ||||||||||||||||
5/20/26 16:15 | 5/18/26 | REPL | Health | BioPrd | Biological Products, (No Diag | Patel Sushil | MA | DO | CEO | 3 | S | -503 | 6.95 | 0 | -72 | 747 | D | |||||||||||||||
5/20/26 16:15 | 5/18/26 | REPL | Health | BioPrd | Biological Products, (No Diag | Hill Emily Luisa | MA | O | CFO | 3 | S | -109 | 5.60 | 0 | -20 | 237 | D | |||||||||||||||
12/11/25 16:30 | 12/9/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Dhingra Kapil | MA | D | 1 | S.d | -33 | 10.40 | 0 | -3 | -100 | 0 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |